Status:
ACTIVE_NOT_RECRUITING
Immune Function as Predictor of Infectious Complications and Clinical Outcome in Patients Undergoing Solid Organ Transplantation
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Transplant
Eligibility:
All Genders
18+ years
Brief Summary
At Rigshospitalet, Denmark, we will examine the immune function of solid organ transplant recipients before and at several timepoints after transplantation as well as the clinical outcome, especially ...
Detailed Description
Background: Solid organ transplantation (SOT) is an increasingly used life-saving treatment for end-stage organ failure. Organ rejection and infections are the main complication to SOT and the balance...
Eligibility Criteria
Inclusion
- To be eligible for the study the participant must be a minimum of 18 years of age, participate in the PERSIMUNE biobank, have a planned kidney, heart, lung, liver or pancreas transplant or be on the waiting list for a heart, lung, liver or pancreas transplant and be able to sufficiently understand oral and written study information in Danish or English to provide an informed consent. Study participation is strictly voluntary
Exclusion
- not meeting inclusion criteria
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2026
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT03847285
Start Date
April 1 2018
End Date
January 31 2026
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100